PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer

Chai,Hong‑Juan; Ren,Qing; Fan,Qin; Ye,Liu; Du,Guang‑Ye; Du,Hua‑Wen; Xu,Wei; Li,Yue; Zhang,Lan; Cheng,Zhong‑Ping

doi:10.3892/ol.2017.6949

PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer

Authors:
- Hong‑Juan Chai
- Qing Ren
- Qin Fan
- Liu Ye
- Guang‑Ye Du
- Hua‑Wen Du
- Wei Xu
- Yue Li
- Lan Zhang
- Zhong‑Ping Cheng
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201999, P.R. China, Department of Gynecology and Obstetrics, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China
Published online on: September 15, 2017 https://doi.org/10.3892/ol.2017.6949
Pages: 5871-5875
Copyright: © Chai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the clinical significance of paired‑box 8 (PAX8) in primary epithelial ovarian cancer (PEOC). Using immunohistochemical (IHC) staining, the expression of PAX8 in 60 patients with PEOC, 20 patients with ovarian benign lesions and 10 patients with metastatic ovarian cancer (MOC), was examined based on the clinicopathological profiles of the patients. The correlation between PAX8 expression and the clinicopathological parameters or prognosis of patients was statistically analyzed. PAX8 was revealed to be highly expressed in PEOC, but not in MOC, as indicated by IHC staining. The rate of positivity of PAX8 in PEOC was 92% (57/60) with no significant difference of PAX8 expression found between the various pathological types of PEOC (P=0.871). The rate of positivity of PAX8 in ovarian benign tumors was 85%, demonstrating no significant difference in comparison with that of PEOC (P=0.761). PAX8 staining and statistical analysis revealed that the higher the grade of PEOC, the less the cancer cell had differentiated (P=0.033) and the more the cancer had advanced according to International Federation of Gynaecological Oncologists (FIGO) staging (P=0.003). Survival rate statistics showed that PEOC patients with higher PAX8 expression exhibited a shorter postoperative survival rate (P=0.009). PAX8 was specifically expressed in PEOC, and its expression level was associated with the degree of cancer cell differentiation, FIGO stage, and survival rate, indicating that PAX8 is a potential marker for the diagnosis of PEOC.

View Figures

View References

1	Sopik V, Lgbal J, Rosen B and Narod SA: Why have ovarian cancer mortality rates declined? Part I. incidence. Gynecol Oncol. 138:741–749. 2015. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004. View Article : Google Scholar : PubMed/NCBI
3	Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, et al: National comprehensive cancer networks: Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 11:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
4	Matias-Guiu X and Davidson B: Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch. 464:315–331. 2014. View Article : Google Scholar : PubMed/NCBI
5	Horn LC, Einenkel J, Handzel R and Höhn AK: Morphology of secondary ovarian tumors and metastases. Pathologe. 35:336–347. 2014.(In German). View Article : Google Scholar : PubMed/NCBI
6	Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y, Liu Y, Takeshita K, Ichinose M, et al: Peritoneal cancer treatment. Expert Opin Pharmacother. 15:623–636. 2014. View Article : Google Scholar : PubMed/NCBI
7	Young RH: From krukenberg to today: The ever present problems posed by metastatic tumors in the ovary: Part I. Historical perspective, general principles, mutinous tumors including the krukenberg tumor. Adv Anat Pathol. 13:205–227. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zhu W and Michael CW: WT1, monoclonal CEA. TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol. 35:370–375. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lee BH, Hecht JL, Pinkus JL and Pinkus GS: WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 117:745–750. 2002. View Article : Google Scholar : PubMed/NCBI
10	Ozcan A, Steven SS, Hamilton C, Anjana K, Coffey D, Krishnan B and Truong LD: PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A cornprehensive immunohistochemical study. Mod Pathol. 24:751–764. 2011. View Article : Google Scholar : PubMed/NCBI
11	Nonaka D, Chiriboga L and Soslow RA: Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 32:1566–1571. 2008. View Article : Google Scholar : PubMed/NCBI
12	Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X, Wright JD and Greenebaum E: PAX8: A marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol. 39:567–574. 2011. View Article : Google Scholar : PubMed/NCBI
13	Mansouri A, Goudreau G and Gruss P: PAX genes and their role in organogenesis. Cancer Res. 59 7 Suppl:S1707–S1710. 1999.
14	Lang D, Powell SK, Plummer RS, Young KP and Ruggeri BA: PAX genes: Roles in development, pathophysiology, and cancer. Biochem Pharmacol. 73:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
15	Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL and Gruss P: Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development. 110:643–651. 1990.PubMed/NCBI
16	Poleev A, Fickenscher H, Mundlos S, Winterpacht A, Zabel B, Fidler A, Gruss P and Plachov D: PAX8, a human paired box gene: Isolation and expression in developing thyroid, kidney and Wilms' tumors. Development. 116:611–623. 1992.PubMed/NCBI
17	Bouchard M, de Caprona D, Busslinger M, Xu P and Fritzsch B: Pax2 and Pax8 cooperate in mouse inner ear morphogenesis and innervation. BMC Dev Biol. 10:892010. View Article : Google Scholar : PubMed/NCBI
18	Mittag J, Winterhager E, Bauer K and Grümmer R: Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology. 148:719–725. 2007. View Article : Google Scholar : PubMed/NCBI
19	Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA and Drapkin R: Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 29:1103–1113. 2010. View Article : Google Scholar : PubMed/NCBI
20	Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD and Ronnett BM: Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: Analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 30:1130–1139. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ordóñez NG: Value of PAX 8 immunostaining in tumor diagnosis: A review and update. Adv Anat Pathol. 19:140–151. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ordóñez NG: Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 26:553–562. 2013. View Article : Google Scholar : PubMed/NCBI
23	Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R and Hirsch MS: PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 34:627–635. 2010.PubMed/NCBI